- Issue price
- ₹162per share
- Issue size
- ₹920 Cr5,67,90,123 shares
- Face value
- ₹2per equity share
- Lot size
- 92 sharesMin. ₹14,904 at the upper price
- Anchor biddingTue, 2025
- OpensWed, 2025
- ClosesFri, 2025
- AllotmentMon, 2025
- ListingWed, 2025
Dates marked in the offer document as tentative. Times in IST.
Information only, not investment advice. This page provides information compiled from official offer documents for information purposes only. It is not investment advice or a recommendation to apply for, buy or sell any security. We are not a SEBI-registered investment adviser or research analyst. Investments in IPOs are subject to market risks; read the offer document carefully before investing.
Issue details
- Issue type
- Book built, fresh issue and offer for sale
- Fresh issue
- 4,75,30,864 shares (₹770 Cr)
- Offer for sale
- 92,59,259 shares (₹150 Cr)
- Total issue
- 5,67,90,123 shares (₹920 Cr)
- Face value
- ₹2
- Listing at
- NSE, BSE
- Promoter holding
- 95.55% → 82.90%
Source: ProspectusUpdated
Reservation
Share of the total issue- Retail35.0%
- Anchor30.0%
- QIB ex-anchor20.0%
- Big NII10.0%
- Small NII5.0%
| Category | Shares | Of net offer | Stated in RHP |
|---|---|---|---|
| Retail individual investors | 1,98,76,544 | 35.00% | 35% |
| Non-institutional investors (NII) | 85,18,519 | 15.00% | 15% |
| Small NII (₹2–10 lakh) | 28,39,506 | 5.00% | — |
| Big NII (above ₹10 lakh) | 56,79,013 | 10.00% | — |
| Qualified institutional buyers (QIB) | 2,83,95,060 | 50.00% | 50% |
| QIB, excluding anchor | 1,13,58,024 | 20.00% | — |
| Anchor investors | 1,70,37,036 | 30.00% | — |
Source: ProspectusUpdated
Lot size
Amounts at ₹162 per share| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail individual investors | 1 | 92 | ₹14,904 |
Source: ProspectusUpdated
Subscription
Category-wise subscription is published by the exchanges while the issue is open. It appears here once the figures are added.
Valuation
FY 2024-25, pre-issue- EPS (basic)
- ₹5.55
- EPS (basic) (Six months ended Sep 30, 2025)
- ₹3.62
- EPS (diluted)
- ₹5.55
- P/E (At floor price, based on FY 2024-25 basic EPS)
- 27.75×
- P/E (At cap price, based on FY 2024-25 basic EPS)
- 29.19×
- NAV per share (As on Sep 30, 2025)
- ₹30
- NAV per share (At offer price)
- ₹44.52
- RoNW
- 20.08%
- ROCE
- 17.47%
- Debt to equity
- 0.61
Source: ProspectusUpdated
Financials
Consolidated, restated · ₹ crore| Period ended | 30 Sep 20256 months | 31 Mar 2025FY 2024-25 | 30 Sep 20246 months | 31 Mar 2024FY 2023-24 | 31 Mar 2023FY 2022-23 |
|---|---|---|---|---|---|
| Revenue from operations | 808.66 | 1,393.57 | 691.51 | 1,231.07 | 1,254.60 |
| Total income | 823.39 | 1,425.97 | 707.48 | 1,263.08 | 1,272.18 |
| EBITDA | 217.14 | 372.17 | 189.59 | 310.30 | 390.34 |
| Profit after tax | 139.14 | 213.21 | 112.88 | 152.00 | 228.17 |
| Net worth | 1,153.05 | 1,021.86 | 923.19 | 815.98 | 667.55 |
| Total assets | 2,320.93 | 2,133.70 | 2,018.73 | 1,912.10 | 1,592.82 |
| Total borrowing | 733.91 | 682.07 | 648.96 | 686.71 | 575.68 |
FY 2024-25 vs FY 2023-24: revenue +13.2%, profit after tax +40.3%. Periods shorter than 12 months are shown as reported and are not annualised.
Source: ProspectusUpdated
About the company
The company runs a chain of NABH-accredited multi-super specialty hospitals under the 'Park' brand, mainly in Haryana, with additional hospitals in Delhi, Punjab and Rajasthan. It has grown through a cluster-based approach that combines new hospital set-ups with acquisitions. Its hospitals offer a wide range of specialties and it has further hospitals under development.
- Incorporated
- 2011
- Industry
- Healthcare
- Sector
- Healthcare and Pharma
- CIN
- U85110DL2011PLC212901
- Website
- parkhospital.in
Source: ProspectusUpdated
Promoters and shareholders
| Name | Type | Before issue | After issue | Shares offered |
|---|---|---|---|---|
| Dr. Ajit Gupta | Promoter | 86.22% | 74.59% | 92,59,259 |
| Dr. Ankit Gupta | Promoter | 9.33% | 8.31% | — |
| Nidhi Gupta | Promoter group | — | — | — |
Source: ProspectusUpdated
Objects of the issue
₹ crore| Purpose | Amount |
|---|---|
| Repayment or prepayment of outstanding borrowings of the company and its subsidiaries | 380.00 |
| Capital expenditure for development of a new hospital by subsidiary Park Medicity (NCR) | 60.50 |
| Capital expenditure for purchase of medical equipment for the company and subsidiaries Blue Heavens and Ratangiri | 27.46 |
| Unidentified inorganic acquisitions and general corporate purposes | 245.32 |
Source: ProspectusUpdated
Peer comparison
As listed in the offer document| Company | EPS | P/E | RoNW | NAV per share |
|---|---|---|---|---|
| Park Mediworld LimitedIssuer | ₹5.55 | — | 20.08% | ₹44.52 |
| Apollo Hospitals Enterprise Limited | ₹100.56 | 73.43× | 17.63% | ₹570.37 |
| Fortis Healthcare Limited | ₹10.26 | 90.42× | 8.69% | ₹118.06 |
| Narayana Hrudalaya Limited | ₹38.9 | 50.10× | 21.80% | ₹177.37 |
| Max Healthcare Institute Limited | ₹11.07 | 101.54× | 11.47% | ₹96.5 |
| Krishna Institute of Medical Sciences Limited | ₹9.61 | 69.53× | 17.89% | ₹53.43 |
| Global Health Limited | ₹17.92 | 66.41× | 14.27% | ₹125.64 |
| Jupiter Lifeline Hospitals Ltd | ₹29.47 | 48.59× | 14.27% | ₹206.85 |
| Yatharth Hospital & Trauma Care Services Limited | ₹14.72 | 52.85× | 8.15% | ₹166.62 |
Source: ProspectusUpdated
Strengths and risks
Our summary of what the offer document statesStrengths
- The company is the second largest private hospital chain in North India and the largest in Haryana by bed capacity.
- It operates a network of 14 NABH-accredited hospitals with a wide range of specialties.
- Bed capacity has grown from 2,550 beds in March 2023 to 3,250 beds in September 2025.
- Its cluster-based model and record of acquiring and integrating hospitals support operating efficiency.
- Revenue and profit have grown in recent periods, supported by a diversified payor mix.
Risks
- Contingent liabilities, including tax and GST demands and corporate guarantees, are significant relative to net worth.
- Revenue is concentrated in hospitals in Haryana, and adverse developments there could hurt results.
- The company depends heavily on doctors and medical staff, and doctor attrition was 33.72% as of September 30, 2025.
- Credit rating downgrades in past years could raise borrowing costs.
- Expansion, acquisitions and new hospital projects may not deliver expected benefits or capacity.
Source: ProspectusUpdated
Documents
Contacts
Source: ProspectusUpdated
Allotment status
Check whether shares were allotted on the official pages below, using your PAN, application number or DP/client ID. Results appear once the basis of allotment is finalised.
- Allotment
- Refunds
- Demat credit
- Listing
Source: ProspectusUpdated
After listing
Listing price, day-one high and low, and the change from the issue price (₹162) appear here after the shares list on NSE and BSE.
Work out the gain or loss on allotted shares after charges and tax →
Frequently asked questions
When does the Park Medi World IPO open and close?
According to the Prospectus, the issue opens on Wednesday, 10 December 2025 and closes on Friday, 12 December 2025.
What is the Park Medi World IPO price band?
The final issue price is ₹162 per share.
What is the lot size of the Park Medi World IPO?
One lot is 92 shares, which is ₹14,904 at ₹162 per share.
Where will Park Medi World shares list?
On NSE and BSE. The tentative listing date is Wednesday, 17 December 2025.
Who is the registrar of the issue?
KFin Technologies Limited (SEBI registration INR000000221). Allotment status is checked on the registrar's website.
How do I check the Park Medi World IPO allotment status?
The basis of allotment is expected to be finalised on Monday, 15 December 2025. After that, search by PAN, application number or DP/client ID on the registrar's website (KFin Technologies Limited), the NSE website or the BSE website. Shares that are allotted are credited to your demat account; for an application that is not allotted, the blocked amount is released.
How will the money raised be used?
₹380 Cr for repayment or prepayment of outstanding borrowings of the company and its subsidiaries, ₹60.5 Cr for capital expenditure for development of a new hospital by subsidiary Park Medicity (NCR), ₹27.46 Cr for capital expenditure for purchase of medical equipment for the company and subsidiaries Blue Heavens and Ratangiri, ₹245.32 Cr for unidentified inorganic acquisitions and general corporate purposes.
Related IPOs
More healthcare and pharma IPOs
- Paras Healthcare₹695Listed · 21 Oct – 23 Oct 2026
- CORONA Remedies₹1,062Listed · 8 Dec – 10 Dec 2025
- VijayPD Ceutical₹35Listed · 29 Sept – 1 Oct 2025
- Aptus PharmaTBAListed · 23 Sept – 25 Sept 2025
Also managed by Nuvama Wealth Management
- SFC Environmental Technologies₹330Listed · 27 Oct – 29 Oct 2026
- Sahajanand Medical Technologies₹344Listed · 15 Oct – 19 Oct 2026
- Fusion CXTBAListed · 14 Oct – 16 Oct 2026
- National Stock Exchange of India₹1,785Listed · 17 Sept – 21 Sept 2026
Spotted something wrong?
Our data comes from official offer documents, but mistakes can slip through. Report an error and tell us which figure looks wrong and where you saw the correct one (the offer-document page number helps). For anything else, see Contact.